Document Detail


Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.
MedLine Citation:
PMID:  16250069     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: This was an exploratory study of olanzapine as potential treatment for improvement in cognition in patients with Alzheimer's disease without prominent psychobehavioral symptoms. METHODS: Non-psychotic/non-agitated patients (n = 268) with Alzheimer's disease, who had baseline Mini-Mental State Examination (MMSE) scores of 14-26 were randomized to treatment with olanzapine (2.5 to 7.5 mg/d) or placebo for 26 weeks. The primary objectives were to determine if treatment with olanzapine improved cognition as indexed by the Alzheimer's disease Assessment Scale for Cognition (ADAS-Cog) and the Clinician's Interview-Based Impression of Change (CIBIC) after 26 weeks of therapy. RESULTS: Patients treated with olanzapine vs placebo experienced significant worsening ADAS-Cog scores at weeks 12 (p = 0.03) and 26 (p = 0.004). Changes in CIBIC scores were not significantly different between treatment groups at either assessment. A post hoc analysis revealed that olanzapine-treated patients with more cognitive impairment at baseline (MMSE scores of 14-18) (n = 35) experienced significantly greater deterioration in ADAS-Cog performance than patients in the placebo group (n = 24; p < 0.001); whereas in patients with less cognitive impairment (n = 78, baseline MMSE scores of 23-26) between-group ADAS-Cog changes were not significant. CONCLUSIONS: In this 26-week study non-psychotic/non-agitated patients with Alzheimer's disease treated with olanzapine experienced significant worsening of cognition as compared to placebo.
Authors:
John Kennedy; Walter Deberdt; Alan Siegal; Joseph Micca; Elisabeth Degenhardt; Jonna Ahl; Adam Meyers; Christopher Kaiser; Robert W Baker
Related Documents :
9850939 - Sustained efficacy and safety of idebenone in the treatment of alzheimer's disease: upd...
20828359 - The action study: methodology of a trial to evaluate safety and efficacy of a higher do...
8418119 - Clinical features distinguishing large cohorts with possible ad, probable ad, and mixed...
17545739 - A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe...
7198209 - Alzheimer disease: lack of effect of lecithin treatment for 3 months.
12605619 - Salvia officinalis extract in the treatment of patients with mild to moderate alzheimer...
23934939 - Outcomes of prolonged exposure therapy for veterans with posttraumatic stress disorder.
22073899 - Desmopressin versus behavioral modifications as initial treatment of primary nocturnal ...
1746279 - Comparative study of affective disorders in three asian countries. ii. differences in p...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of geriatric psychiatry     Volume:  20     ISSN:  0885-6230     ISO Abbreviation:  Int J Geriatr Psychiatry     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-11-22     Completed Date:  2006-06-01     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  8710629     Medline TA:  Int J Geriatr Psychiatry     Country:  England    
Other Details:
Languages:  eng     Pagination:  1020-7     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2005 John Wiley & Sons, Ltd.
Affiliation:
University of Alberta and Chinook Regional Health System, Alberta, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Alzheimer Disease / drug therapy,  psychology*
Antipsychotic Agents / adverse effects,  therapeutic use*
Benzodiazepines / adverse effects,  therapeutic use
Cognition Disorders / drug therapy*,  etiology
Disease Progression
Double-Blind Method
Female
Humans
Male
Middle Aged
Neuropsychological Tests
Prospective Studies
Psychiatric Status Rating Scales
Psychomotor Agitation
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Investigation of the mechanism of resistance to third-generation cephalosporins by class C beta-lact...
Next Document:  The utility of EEG in dementia: a clinical perspective.